Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-21-012662

Chief Scientific Officer sold 800 shares at an average $36.27 ($29,018)

  • Chief Scientific Officer acquired 800 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2021-02-18 Exercise or conversion : show line 1 in the form +800 $7.26 $5,808 12,800 D
2021-02-18 Sale : show line 2 in the form −600 $35.81 $21,484 12,200 D
2021-02-18 Sale : show line 3 in the form −200 $37.67 $7,534 12,000 D
Open-market sales · 800 sh · avg $36.27 · $29,018

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2021-02-18 Exercise or conversion : show line 4 in the form Employee Stock Option (right to buy) −800 $7.26 2030-02-26 800 75,866 D
Loading xslF345X03/doc4.xml…